Drug Patent Expirations in September 2012

Drug Patent Expirations for September 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
GEODON Pfizer Inc ziprasidone hydrochloride 5,312,925 Sep 1, 2012
GEODON Pfizer ziprasidone hydrochloride 5,312,925 Sep 1, 2012
BESIVANCE Bausch And Lomb besifloxacin hydrochloride 5,447,926 Sep 5, 2012
ALREX Bausch And Lomb loteprednol etabonate 4,996,335*PED Sep 9, 2012
ZYLET Bausch And Lomb loteprednol etabonate; tobramycin 4,996,335*PED Sep 9, 2012
LOTEMAX Bausch And Lomb loteprednol etabonate 4,996,335*PED Sep 9, 2012
EMEND Merck And Co Inc fosaprepitant dimeglumine 7,214,692 Sep 18, 2012
EMEND Merck aprepitant 7,214,692 Sep 18, 2012
EXFORGE Novartis amlodipine besylate; valsartan 5,399,578*PED Sep 21, 2012
DIOVAN Novartis valsartan 5,399,578*PED Sep 21, 2012
LATISSE Allergan bimatoprost 6,403,649 Sep 21, 2012
EXFORGE HCT Novartis amlodipine besylate; hydrochlorothiazide; valsartan 5,399,578*PED Sep 21, 2012
DIOVAN HCT Novartis hydrochlorothiazide; valsartan 5,399,578*PED Sep 21, 2012
LUMIGAN Allergan bimatoprost 6,403,649 Sep 21, 2012
SYMBICORT Astrazeneca budesonide; formoterol fumarate dihydrate 6,641,800 Sep 23, 2012
DETROL LA Pharmacia And Upjohn tolterodine tartrate 5,382,600*PED Sep 25, 2012
TIKOSYN Pfizer dofetilide 4,959,366 Sep 25, 2012
DETROL Pharmacia And Upjohn tolterodine tartrate 5,382,600*PED Sep 25, 2012
NIMBEX PRESERVATIVE FREE Abbvie cisatracurium besylate 5,453,510 Sep 26, 2012
NIMBEX Abbvie cisatracurium besylate 5,453,510 Sep 26, 2012
REVATIO Pfizer sildenafil citrate 5,250,534*PED Sep 27, 2012
VIAGRA Pfizer Ireland sildenafil citrate 5,250,534*PED Sep 27, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

Comments are closed.